JP2023500480A - 癌の治療のための抗ｃｄ２７抗体の投薬計画 - Google Patents

癌の治療のための抗ｃｄ２７抗体の投薬計画 Download PDF

Info

Publication number
JP2023500480A
JP2023500480A JP2022525094A JP2022525094A JP2023500480A JP 2023500480 A JP2023500480 A JP 2023500480A JP 2022525094 A JP2022525094 A JP 2022525094A JP 2022525094 A JP2022525094 A JP 2022525094A JP 2023500480 A JP2023500480 A JP 2023500480A
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
administered
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500480A5 (https=
JPWO2021087016A5 (https=
Inventor
チャータッシュ，エリオット・ケー
ビービ，エイミー・エム
チェン，ジャイソン・ケー
ドブレンコフ，コンスタンティン
リー，クレア・エイチ
ヴネク，リチャード
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2023500480A publication Critical patent/JP2023500480A/ja
Publication of JP2023500480A5 publication Critical patent/JP2023500480A5/ja
Publication of JPWO2021087016A5 publication Critical patent/JPWO2021087016A5/ja
Priority to JP2025131369A priority Critical patent/JP2025170788A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022525094A 2019-11-01 2020-10-29 癌の治療のための抗ｃｄ２７抗体の投薬計画 Pending JP2023500480A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025131369A JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗ｃｄ２７抗体の投薬計画

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962929538P 2019-11-01 2019-11-01
US62/929,538 2019-11-01
PCT/US2020/057817 WO2021087016A1 (en) 2019-11-01 2020-10-29 Dosing regimen of anti-cd27 antibodies for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025131369A Division JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗ｃｄ２７抗体の投薬計画

Publications (3)

Publication Number Publication Date
JP2023500480A true JP2023500480A (ja) 2023-01-06
JP2023500480A5 JP2023500480A5 (https=) 2023-11-08
JPWO2021087016A5 JPWO2021087016A5 (https=) 2023-11-08

Family

ID=75716307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525094A Pending JP2023500480A (ja) 2019-11-01 2020-10-29 癌の治療のための抗ｃｄ２７抗体の投薬計画
JP2025131369A Pending JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗ｃｄ２７抗体の投薬計画

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025131369A Pending JP2025170788A (ja) 2019-11-01 2025-08-06 癌の治療のための抗ｃｄ２７抗体の投薬計画

Country Status (10)

Country Link
US (1) US20230192876A1 (https=)
EP (1) EP4051712A4 (https=)
JP (2) JP2023500480A (https=)
KR (1) KR20220092569A (https=)
CN (1) CN114761432A (https=)
AU (1) AU2020372912A1 (https=)
BR (1) BR112022008233A2 (https=)
CA (1) CA3159366A1 (https=)
MX (1) MX2022005245A (https=)
WO (1) WO2021087016A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12162940B2 (en) 2021-05-05 2024-12-10 Immatics Biotechnologies Gmbh BMA031 antigen binding polypeptides
WO2025188553A1 (en) * 2024-03-05 2025-09-12 Merck Sharp & Dohme Llc Methods and compositions for treatment of cancer with anti-cd27 antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170368172A1 (en) * 2015-12-17 2017-12-28 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
WO2018058022A1 (en) * 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011275749C1 (en) * 2010-07-09 2015-09-17 Aduro Biotech Holdings, Europe B.V. Agonistic antibody to CD27

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170368172A1 (en) * 2015-12-17 2017-12-28 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
WO2018058022A1 (en) * 2016-09-26 2018-03-29 Merck Sharp & Dohme Corp. Anti-cd27 antibodies

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healt", GUIDANCE FOR INDUSTRY, JPN6021034319, 2005, pages 1 - 27, ISSN: 0005567692 *
REARDON DAVID A ET AL, 'ANTI-CD27 AGONIST ANTIBODY VARLILUMAB IN COMBINATION WITH NIVOLUMAB FOR RECURRENT GLIOBLASTOMA: PHA, JPN6024037518, 17 November 2018 (2018-11-17), pages 1, ISSN: 0005567691 *

Also Published As

Publication number Publication date
BR112022008233A2 (pt) 2022-07-26
EP4051712A1 (en) 2022-09-07
MX2022005245A (es) 2022-06-08
AU2020372912A1 (en) 2022-05-26
WO2021087016A1 (en) 2021-05-06
KR20220092569A (ko) 2022-07-01
CA3159366A1 (en) 2021-05-06
US20230192876A1 (en) 2023-06-22
JP2025170788A (ja) 2025-11-19
EP4051712A4 (en) 2023-11-29
CN114761432A (zh) 2022-07-15

Similar Documents

Publication Publication Date Title
JP7745527B2 (ja) 抗ｓｉｒｐアルファ抗体
JP7379345B2 (ja) 抗ｐｄ－１／ｌａｇ３二重特異性抗体
TWI854952B (zh) 抗cd27抗體
US12122834B2 (en) Anti-PD-1 antibodies
JP2022546922A (ja) 抗ｐｄ－１／ｌａｇ３／ｔｉｇｉｔ三重特異性抗体および抗ｐｄ－１／ｌａｇ３二重特異性抗体
JP2025170788A (ja) 癌の治療のための抗ｃｄ２７抗体の投薬計画
NL2018708B1 (en) ANTI-SIRPα ANTIBODIES
WO2025188553A1 (en) Methods and compositions for treatment of cancer with anti-cd27 antibodies

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20220916

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408